Acute myeloid leukemia (AML) is genetically complex, but patients can be divided into those with chromosomal translocations and those that are cytogenetically normal (CN-AML). CN-AML represents nearly 50% of human AML cases, and the overall 5-year survival for adults with CN-AML is approximately 30%. Mutations in the de novo DNA methyltransferase DNMT3A and internal tandem duplications of the FMS-like tyrosine kinase 3 (FLT3-ITD) and are two of the most frequent events in CN-AML. Moreover, recent whole-genome sequencing of CN-AML patient samples identified: 1) high-frequency co-occurrence of FLT3 and DNMT3A mutations, and 2) corresponding changes to the risk classification for these CN-AML patients to a poorer prognosis. Because human epidemiologic studies cannot easily control for factors that confer disease risk, genetically engineered mouse (GEM) strains provide essential tractable platforms to mechanistically dissect disease pathobiology, heterogeneity and therapeutic response. Although neither Flt3-ITD nor inducible deletion of Dnmt3a induces spontaneous leukemia in mice, when we combined Flt3-ITD mutant alleles with inducible deletion of Dnmt3a we find a spontaneous, rapidly lethal, completely-penetrant, and transplantable AML. We hypothesize that inducible deletion of Dnmt3a in Flt3-ITD mice produces a faithful model of human CN-AML that can be used to infer essential biological and molecular factors that constitute therapeutic response. To this end, we propose, genomic, cytogenetic, and single-cell molecular analyses (with comparison to primary human CN-AML) to deconvolute both the tumor architecture and the underlying cellular states. We expect the proposed research to deliver a validated murine model of FLT3-ITD/DNMT3a-mutant CN-AML with defined translational utility.
To address pressing biological and therapeutic questions, this project will validate genetically-defined animal models of acute myeloid leukemia (AML) that are cytogenetically normal (CN-AML). The overall 5-year survival for adults with CN-AML is approximately 30%. The proposed work will deliver a validated murine model of CN-AML with two frequently co-occurring mutations. We expect the work to provide a platform to test new therapeutic interventions, as well as to define the target cells and gene expression relevant to efficacy.
|Dwivedi, Pankaj; Muench, David E; Wagner, Michael et al. (2018) Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. Leukemia :|
|Hay, Stuart B; Ferchen, Kyle; Chetal, Kashish et al. (2018) The Human Cell Atlas bone marrow single-cell interactive web portal. Exp Hematol 68:51-61|
|Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136|
|Muench, David E; Ferchen, Kyle; Velu, Chinavenmeni S et al. (2018) SKI controls MDS-associated chronic TGF-? signaling, aberrant splicing, and stem cell fitness. Blood 132:e24-e34|
|Meyer, Sara E; Qin, Tingting; Muench, David E et al. (2016) DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov 6:501-15|